Modulación de las cinasas dependientes de ciclinas como nueva estrategia terapéutica

Vermeulen, 2003, The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer, Cell Prolif, 36, 131, 10.1046/j.1365-2184.2003.00266.x Harbour, 1999, Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1, Cell, 98, 859, 10.1016/S0092-8674(00)81519-6 Morgan, 1995, Principles of CDK regulation, Nature, 374, 131, 10.1038/374131a0 Zindy, 1999, Postnatal neuronal proliferation in mice lacking INK4d and KIP1 inhibitors of cyclin-dependent kinases, Proc Natl Acad Sci USA, 96, 13462, 10.1073/pnas.96.23.13462 Sedlacek, 2001, Mechanisms of action of flavopiridol, Crit Rew Oncol Hematology, 38, 139, 10.1016/S1040-8428(00)00124-4 Maccioni, 2001, The protein kinase Cdk5, Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology. Eur J Biochem, 268, 1518 Chao, 2000, Flavopi-ridol inhibits P-TEFb and blocks HIV-1 replication, J Biol Chem, 275, 28345, 10.1074/jbc.C000446200 Melillo, 1999, Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes, Cancer Res., 59, 5433 Brusselbach, 1998, Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells, Int J Cancer, 77, 146, 10.1002/(SICI)1097-0215(19980703)77:1<146::AID-IJC22>3.0.CO;2-B Lee, 1999, Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line, Int J Oncol., 15, 161 Hagenauer, 2001, In Vitro Glucuronidation of the Cyclin-Depen-dent Kinase Inhibitor Flavopiridol by Rat and Human Liver Microsomes: Involvement of UDP-Glucuronosyltransferases 1A1 and 1A9, Drug Metab Dispos, 29, 407 Ramirez, 2002, In Vitro Characterization of Hepatic Flavopiridol Metabolism Using Human Liver Microsomes and Recombinant UGT Enzymes, Pharmaceutical Research, 19, 588, 10.1023/A:1015341726183 Senderowicz, 1999, Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials, Invest New Drugs, 17, 313, 10.1023/A:1006353008903 Senderowicz, 1998, Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms, J Clin Oncol., 16, 2986, 10.1200/JCO.1998.16.9.2986 Kahn, 2001, Possible mechanisms of diarrheal side effects associated with the use of a novel chemothera-peutic agent, flavopiridol, Clin Cancer Res., 7, 343 Messmann, 2003, Flavopiridol-related proinflamatory syndrome is associated with induction of interleukin-6, Clin Cancer Res., 9, 562 Rudek, 2003, Clinical pharmacology of flavopiridol following a 72 hour continuous infusion, Ann Pharmacother, 37, 1369, 10.1345/aph.1C404 Innocenti, 2000, Flavo-piridol metabolism in cancer patients is associated with the occurrence of diarrhea, Clin Cancer Res., 6, 3400 Thomas, 1997, Phase I clinical and pharmacokinetic trial of flavopiridol, Proc Am Assoc Cancer Res, 38, 222 Schwartz, 2001, Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma, J Clin Oncol., 19, 1985, 10.1200/JCO.2001.19.7.1985 Stadler, 2000, Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study, J Clin Oncol., 18, 371, 10.1200/JCO.2000.18.2.371 Shapiro, 2001, A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer, Clin Cancer Res., 7, 1590 Aklilu, 2003, Phase II study of flavopiridol in patients with advanced colorectal cancer, Ann Oncol, 14, 127, 10.1093/annonc/mdg343 Kouroukis, 2003, Flavo-piridol in untreated or relapsed mantle-cell lymp-homa:results of a phase II study of the national cancer institute of Canada trials group, J Clin Oncol., 21, 1740, 10.1200/jco.2003.09.057 Zhai, 2003, Clinical pharmacology and pharmacogenomics of flavopiridol 1h-iv infusion in patients with refractory neoplasms, Anticancer drugs, 14, 125, 10.1097/00001813-200302000-00006 Senderowicz, 2000, A phase I trial of 1 hour infusion of flavopiri-dol (FLA), a novel cyclin-dependent kinase inhibitor, in patients with advanced neoplasms, Proc Am Soc Clin Oncol., 204a Tan, 2002, Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol, 20, 4074 Cancer.gov. National Cancer Institute. Clinical trials. 10 Octubre 2003 Disponible en web: www.nci.nih.gov/clinicaltrials/. Bible, 1997, Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration, Cancer Res., 57, 3375 Grant, 2003, The use of cyclin dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy, Drug Resist Updat., 6, 15, 10.1016/S1368-7646(02)00141-3 Schwartz, 1999, Phase I trial of sequential paclitaxel and the cyclin dependent kinase inhibitor flavopiridol, Proc Am Soc Clin Oncol., 160ª Seynaeve, 1994, Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue, Mol Pharmacol., 45, 1207 Busby, 2000, The radiosensitizing agent 7-hydroxystaurospo-rine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1, Cancer Res., 60, 2108 Sausville, 2001, Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms, J Clin Oncol., 19, 2319, 10.1200/JCO.2001.19.8.2319 Sausville, 1998, Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models, Cancer Chemother Pharmacol., 42, S54, 10.1007/s002800051080 Fuse, 1998, Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein, Cancer Res., 58, 3248 Tamura, 1999, Phase I study of UCN-01 by 3-hour infusion, Proc Am Soc Clin Oncol., 18, 159a Zaharevitz, 1999, Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases, Cancer Res., 59, 2566 Hoessel, 1999, Indi-rubin, the active component of a Chinese anti-leukemia medicine, inhibits cyclin dependent kinases, Nat Cell Biol., 1, 60, 10.1038/9035 Havlicek, 1997, Cytoki-nin-Derived Cyclin-Dependent Kinase Inhibitor: Synthesis and cdc2. Inhibitory Activity of Olo-moucine and Related Compounds, J. Med. Chem., 40, 408, 10.1021/jm960666x Senderowicz, 2002, Cyclin dependent kinases as new targets for the prevention and treatment of cancer, Hematol Oncol Clin North Am., 16, 1229, 10.1016/S0889-8588(02)00049-7 Senderowicz, 2002, Cyclin dependent kinases a targets for cancer therapy, Cancer Chemother Biol Response Modif., 20, 169 Senderowicz, 2003, Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms, Cancer Chemoth Pharm, 52, 61, 10.1007/s00280-003-0624-x Senderowicz, 2003, Small molecule cyclin-dependent kinases modulators, Oncogene, 22, 6609, 10.1038/sj.onc.1206954